N-of-One® Interprets 4,000th Sequenced Tumor, Revealing Therapeutic Options Beyond the Standard of Care for More than 70% of Cancer Patients

WALTHAM, Mass.--(BUSINESS WIRE)--N-of-One Therapeutics, Inc., the leading provider of molecular interpretation and therapeutic strategies for personalized cancer care since 2008, today announced that it has analyzed and interpreted its 4,000th cancer patient tumor, an industry milestone.

Help employers find you! Check out all the jobs and post your resume.